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Abstract
Background: This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of
the 3 most commonly prescribed atypical antipsychotics – olanzapine, quetiapine, or risperidone.
Methods: Data were drawn from a large, prospective, naturalistic, multi-site, nonrandomized study of treatment
for schizophrenia in the United States conducted between July 1997 and September 2003. Participants who were
initiated on olanzapine (N = 405), quetiapine (N = 115), or risperidone (N = 276) were followed for 1 year post
initiation and compared on: (a) average daily cost of the index antipsychotic while on the index antipsychotic, (b)
average daily cost of the coprescribed antipsychotics while on the index antipsychotic, (c) average daily cost of
the index antipsychotic and the coprescribed antipsychotics while on the index antipsychotic, (d) total annual cost
of antipsychotic medications prescribed in the year following initiation on the index antipsychotic, using
propensity score-adjusted bootstrap resampling method. Average daily antipsychotic costs and total annual
antipsychotic costs were also estimated using more recent (2004) antipsychotic drug prices.
Results: During the 1 year following initiation on the index antipsychotic, the total average daily cost of the index
antipsychotic was higher for quetiapine ($15.33) than olanzapine ($13.90, p < .05) and risperidone ($11.04, p <
.01), although the average daily cost of the index antipsychotic was higher for olanzapine ($10.08) than risperidone
($6.74, p < .01) or quetiapine ($6.63, p < .01). Lower total average daily costs were observed in risperidone than
olanzapine or quetiapine. Significantly lower average daily cost of concomitant antipsychotic medications for
olanzapine ($3.82) compared to quetiapine ($8.70, p < .01) or risperidone-initiated patients ($4.30, p < .01)
contributed to the lower average daily cost of all antipsychotic medication for olanzapine-initiated patients. Each
dollar spent on the index antipsychotic was accompanied by spending an additional $1.31 on concomitant
antipsychotics for quetiapine compared to $0.64 for risperidone and $0.38 for olanzapine-initiated patients. A
separate intent-to-treat analysis of the total annual antipsychotic cost found a significantly higher total annual
antipsychotic cost for quetiapine-initiated patients ($5320) compared to olanzapine ($4536, p < .01) or
risperidone ($3813, p < .01).
Conclusion: Prevalent antipsychotic polypharmacy adds substantial cost to the treatment of schizophrenia.
Comparison of medication costs need to address the costs of all antipsychotics. A better understanding of
concomitant antipsychotic costs provides a more accurate portrayal of antipsychotic medication costs in the
treatment of schizophrenia.
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Background
Antipsychotic medications have been a core treatment
modality in the treatment of patients with schizophrenia
over the past 40 years with antipsychotic monotherapy
being the treatment of choice [1]. Despite consistent rec-
ommendations of antipsychotic monotherapy, antipsy-
chotic polypharmacy is commonplace in the treatment of
schizophrenia [2-9]. Polypharmacy – the concomitant use
of 2 or more antipsychotics – has been reported to range
between 13% and 60% depending on the population
studied, the year the study was conducted, the study
method, the type of treatment site, and the duration of the
study period [7,9-14]. Our recent study using data from an
observational noninterventional study [15] found that
over a 1-year study period only a third of the schizophre-
nia patients were treated predominantly with antipsy-
chotic monotherapy, whereas 58% of schizophrenia
patients had at least 1 period of antipsychotic polyphar-
macy lasting longer than 60 consecutive days.
In recent years as additional atypical antipsychotics with
different pharmacological properties have become availa-
ble for the treatment of schizophrenia, the likelihood of
combining antipsychotics has increased [16,17]. The rate
and duration of antipsychotic polypharmacy was previ-
ously shown to significantly differ among atypical antip-
sychotics [5,9], as olanzapine-initiated patients were often
found more likely to be treated on monotherapy while
quetiapine-initiated patients were more likely to be
treated with polypharmacy [10,13,15,18-23].
While the clinical benefits of antipsychotic polypharmacy
are unclear and poorly documented [5,9,24-26], the use
of polypharmacy may also hinder clinicians' ability to
accurately evaluate a patient's response to a new course of
treatment [2]. It also increases the complexity of the med-
ication regimen and risk of adverse events and makes it
more difficult to assess and manage future symptom exac-
erbations [5]. Moreover, polypharmacy increases antipsy-
chotic treatment costs at a time of growing budget
constraints across systems of care [5,8,19]. Despite con-
cerns about economic consequences of antipsychotic
polypharmacy, most recent studies on antipsychotic med-
ication costs have focused mainly on index atypical drug
acquisition costs, and no information is yet available on
differential cost of polypharmacy during the usual care of
schizophrenia with commonly prescribed atypical antip-
sychotics.
To fill the gap in knowledge and expand on previous find-
ings, we used data from a large, prospective, noninterven-
tional, observational study in the United States to assess
the cost of antipsychotic polypharmacy during the long-
term treatment of schizophrenia patients in usual care. We
have calculated the average daily cost of each "index"
antipsychotic (olanzapine, risperidone, and quetiapine)
and the average daily cost of the coprescribed antipsychot-
ics by medication type (typical and atypical). In addition
to average daily costs, this study also used an intent-to-
treat approach to assess the total annual costs of all antip-
sychotic medications prescribed in the year following ini-
tiation on each index atypical antipsychotic. To enhance
relevance of the findings, the average daily and total
annual costs of antipsychotic polypharmacy were also
estimated using more recent (2004) drug prices.
Methods
Data source and sample selection
This study used data from the U.S. Schizophrenia Care
and Assessment Program (US-SCAP), a large, nonrand-
omized, naturalistic, 3-year prospective, multi-site study
conducted between July 1997 and September 2003. The
goal of US-SCAP was to understand the treatment of
patients with schizophrenia in usual care settings. Briefly,
participants were enrolled from 6 regional sites (Califor-
nia, Colorado, Connecticut, Florida, Maryland, and North
Carolina) and diverse systems of care, including commu-
nity mental health centers, university health care systems,
the Department of Veterans Affairs Health Services (VA),
and community and state hospitals. Participants were
diagnosed with schizophrenia, or schizoaffective or schiz-
ophreniform disorder, based on DSM-IV criteria and were
at least 18 years of age. Individuals were excluded from
the study if they were unable to provide informed consent
or had participated in a clinical drug trial within 30 days
prior to enrollment. Further details regarding US-SCAP
are available elsewhere [15,27,28].
A total of 2327 participants were enrolled from 6 states
and represented treatment in diverse systems of care
including community mental health centers, university
health care systems, the Department of Veterans Affairs
Health Services (VA), and state hospitals. Institutional
Review Board (IRB) approval was received at each
regional site, and informed consent was received from all
participants.
The current study identified 2276 of the 2327 total partic-
ipants in the study who used antipsychotics during the 3-
year study period. Among those antipsychotic users, a
total of 796 of olanzapine, risperidone, and quetiapine
users who met the "initiator" criteria were identified (Fig-
ure 1). Participants were defined as initiators if they were
not prescribed the index antipsychotic (olanzapine, risp-
eridone, quetiapine) for at least 60 days prior to initiation
and had at least 2 months of data available prior to and at
least 12 months of data post initiation of the index antip-
sychotic. Inclusion of data for the 2 months prior to initi-
ation allowed for the identification of variables on which
the treatment groups differed at the time of initiation. Fur-BMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
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ther, because this study aimed to assess use of antipsy-
chotics over a 1-year period, availability of a 12-month
follow-up period was necessary. This resulted in an initial
analytical sample of 1030 (484, 361, 185 for olanzapine,
risperidone, and quetiapine, respectively) participants.
However, since some participants had more than 1 initia-
tion on an index drug during the 3-year study, the final
analytical sample (N = 796) included the participants'
first initiation on the index medication in standard oral
formulation resulting in 3 medication initiation groups:
olanzapine (N = 405), quetiapine (N = 115), and risperi-
done (N = 276). Participants were not excluded from the
analysis if they: (1) stopped their antipsychotic therapy as
long as they completed the 1-year study, (2) initiated on
another antipsychotic(s), and (3) augmented with other
antipsychotics during the study.
Outcome measures
Medical records provided information on all prescribed
antipsychotics and were systematically abstracted by
trained examiners for the 6 months prior to enrollment
and for each 6-month interval thereafter. Patients were
queried on the use of medications and other mental
health resources outside those received at their regular
treatment site. When this occurred, systematic efforts were
made to abstract out-of-site medical records.
Antipsychotic medication costs were calculated on: (1)
average daily cost of the index antipsychotic while
patients were on the index antipsychotic, (2) average daily
cost of the coprescribed antipsychotics while patients
were on their index antipsychotic, (3) average daily cost of
both the index and coprescribed antipsychotics while
patients were on their index antipsychotic, and (4) total
annual cost of antipsychotic medications prescribed in the
year following initiation on the index antipsychotic. The
first episode following initiation for each index medica-
tion was used to calculate the average daily cost of antip-
sychotic medication. The first episode following initiation
was the total number of days from the date of initiation of
the index drug to the first medication gap of more than 30
days. The total annual antipsychotic costs were the sum of
all antipsychotic medication costs incurred during the 1-
year post initiation of the index antipsychotic. Further-
more, to provide a more recent cost estimate, the daily
costs and annual costs were also estimated using more
recent (2004) antipsychotic drug prices.
Patient Disposition Figure 1
Patient Disposition. Disposition of patients initiated on any antipsychotic during the 3-year study and by antipsychotic drug.BMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
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The actual dose and frequency of each prescribed antipsy-
chotic was identified for each patient for each day on the
index antipsychotic and the coprescribed antipsychotic(s)
during the 1 year following its initiation. This information
was used to calculate the average daily costs and the annual
costs. The average daily cost for each index antipsychotic
and coprescribed antipsychotic (by type of coprescribed
antipsychotic: typical or atypical) was calculated by mul-
tiplying the average daily dose of that antipsychotic
incurred during the index treatment episode by the
median milligram Average Wholesale Price (AWP) pub-
lished for the study year of that antipsychotic, discounted
by 15% for atypical antipsychotics to better reflect dis-
count practices in the United States. Antipsychotic costs
were based on AWP for 1998–1999, because these years
constituted the midpoint in patients' enrollment in US-
SCAP. For comparison purposes, a sensitivity analysis on
the antipsychotic costs was also calculated based on
2004's AWP when the analysis for this study was con-
ducted. We assume that AWP will reflect the inflation of
costs, and no further adjustment based on inflation rate
was made.
Statistical methods
For the summary statistics, group comparisons were made
on baseline characteristics using ANOVA for continuous
variables and Mantel-Haenszel chi-square tests for cate-
gorical variables. In order to test the mean differences in
average daily or total annual medication costs between
the treatment groups, propensity score-adjusted bootstrap
resampling method [29] was used with a set of a priori
defined variables as adjustment. Patient demographic and
available clinical characteristics (age, gender, race, illness
duration, schizoaffective diagnosis, insurance, comorbid
substance use disorder, psychiatric hospitalization at ini-
tiation, time elapsed between medication initiation and
beginning of the study, and enrollment site) was included
in the logistic models to calculate the propensity score for
each patient. Propensity score-adjusted bootstrapping
method analyzes mean differences of costs or days on
medication by first calculating the logit score for each
patient based on the above adjustments. There were 5 bins
of logit scores created then for each treatment group.
Bootstrap resampling method was then performed by ran-
domly selecting an equal size of sample from each of the
10 bins (5 bins for each treatment) into 1 group and cal-
culating the total cost difference between the 2 treatment
groups compared. After 1000 times of iteration, the 1000
data points generated are tested using 2-tailed p-values.
The same statistical approach was used to compare the
average daily and total annual antipsychotic medication
costs estimated using the 2004 drug prices. All statistical
tests were 2-tailed, and significance was set at alpha of
0.05. SAS version 8.2 was used to perform all statistical
analyses, and statistical significance was at a 2-sided alpha
level of 0.05.
Results
Patient characteristics
Among the 2327 patients enrolled in this naturalistic,
observational study, a total of 796 patients met inclusion
criteria in this initiator's analysis: 405 were initiated on
olanzapine, 276 on risperidone, and 115 on quetiapine
(Figure 1). The average age for the patients in this study
was 41.0 ± 11.0 years, and the average age of illness onset
was 19.9 ± 8.8 years. The majority of the patients were
male (57.3%) and had Medicaid and/or Medicare insur-
ance coverage (82.1%). At the time of initiation on the
index antipsychotic, the 3 treatment groups did not signif-
icantly differ on age, ethnicity, diagnosis of schizoaffective
disorder, or uninsured status (Table 1). The groups, how-
ever, differed significantly (p < .05) on gender, substance
use, and hospitalization status at the time of initiation.
The quetiapine-initiated group was more likely to be
female, of shorter illness duration, and lower likelihood
of comorbid diagnosis of substance use disorder. The ris-
peridone-initiated patients were more likely to be initi-
ated on the drug during a psychiatric hospitalization, and
the olanzapine-initiated group had longer illness duration
and more patients with veteran status. As noted earlier,
these baseline characteristics were included as covariates
in the statistical models used to analyze cost differences
between the groups.
Cost of all antipsychotic medications
Annual antipsychotic medication costs
The cost of an antipsychotic medication is affected by its
dose and the duration of treatment with the respective
drug. For the 3 atypicals used in the study, the average
(median) dose was 13.9 (10.0) for olanzapine, 330 (395)
for quetiapine, and 4.3 (3.9) for risperidone. The average
daily doses in mg/day of the index atypical antipsychotics
during the 1-year post initiation were within the package
insert guidelines.
In the 1-year post initiation, the olanzapine group had an
average of 280 days on olanzapine (Table 2) and a medi-
cation acquisition cost of $3005 (Table 3) compared to
260 days on risperidone with medication acquisition
costs of $1878 (p < .01) and 239 days on quetiapine with
medication acquisition costs of $1881 (p < .01). During
the same 1-year period, the quetiapine-initiated group
incurred significantly higher costs from the use of other
antipsychotics ($3439) compared to the risperidone
($1936, p < .01) and the olanzapine treatment groups
($1530, p < .01). As a result, the quetiapine-initiated
group incurred significantly higher annual total cost of all
antipsychotic medications ($5320) compared to olanzap-
ine ($4536, p < .01) or risperidone ($3813, p < .01)BMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
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(Table 3). The lower cost of the olanzapine group and the
higher cost of the quetiapine group appear to be largely
driven by longer days of concurrent first-generation antip-
sychotics in the olanzapine-treated patients (i.e., olanzap-
ine: 105 days, risperidone: 79.3 days, quetiapine: 69.4
days, with a reverse pattern being true for cotreatment
with atypicals (i.e., olanzapine: 36.1 days, risperidone:
49.4 days, quetiapine: 110.6 days).
Table 1: Comparison of baseline demographics and clinical characteristics of the study patients.
Variables OLZ
(N = 405)
RIS
(N = 276)
QUE
(N = 115)
p-value
Age at Baseline 41.8(10.5) 40.4(12.1) 39.62(10.9) 0.0826
Age of Illness Onset 19.5(8.3) 20.0(9.2) 21.0(9.9) 0.2516
Gender (% Male) 61.7%(n = 250) 54.7%(n = 151) 47.8%(n = 55) 0.0165
Race (%) 0.2584
White 46.7%(n = 189) 45.3%(n = 125) 53.9%(n = 62)
Black 41.2%(n = 167) 36.6%(n = 101) 33.9%(n = 39)
Hispanic 8.9%(n = 36) 13.8%(n = 38) 8.7%(n = 10)
Others 3.2%(n = 13) 4.4%(n = 12) 3.5%(n = 4)
Insurance (%) 0.5837
Medicaid/Medicare 83.0%(n = 327) 80.2%(n = 218) 83.9%(n = 94)
Champus/VA 6.8%(n = 27) 5.2%(n = 14) 2.7%(n = 3)
Private/HMO 2.3%(n = 9) 4.0%(n = 11) 2.7%(n = 3)
Other Insurance 1.0%(n = 4) 1.5%(n = 4) 1.8%(n = 2)
No Insurance 6.8%(n = 27) 9.2%(n = 25) 8.9%(n = 10)
Marriage Status (% single) 63.0%(n = 254) 57.8%(n = 129) 61.7%(n = 71) 0.3885
Education (% High School or Less) 71.6%(n = 287) 63.9%(n = 175) 67.3%(n = 76) 0.1046
Comorbidity
Diagnosis of Substance use (%) 30.9%(n = 125) 29.4%(n = 81) 19.1%(n = 22) 0.0467
Diagnosis of Mental Retardation (%) 7.6%(n = 31) 6.2%(n = 17) 8.7%(n = 10) 0.626
Diagnosis of Personality (%) 18.3%(n = 74) 13.0%(n = 36) 20.9%(n = 24) 0.0925
Diagnosis of Borderline (%) 2.7%(n = 11) 2.9%(n = 8) 5.2%(n = 6) 0.3827
Diagnosis of Mental Retardation or Borderline (%) 10.4%(n = 42) 8.3%(n = 23) 13.0%(n = 15) 0.3529
Schizoaffective disorder diagnosis at enrollment (%) 39.6%(n = 132) 33.3%(n = 92) 40%(n = 46) 0.3239
Hospitalization Status on Initiation day (%) 12.8%(n = 52) 22.1%(n = 61) 13.9%(n = 16) 0.0043
MADRS Score at Enrollment 15.6(10.3) 15.5(11.4) 16.3(11.4) 0.8006
PANSS Total at Enrollment 73.2(18.4) 72.9(18.9) 73.6(17.74) 0.9451
Total days on index drug post 1 year after initiation 280(121) 260(134) 239(136) 0.0048
Total days CONTINUOUSLY on index drug post 1-year after initiation 272(129) 250(1431) 225(147) 0.0023
Table 2: Total days on index drugs and concomitant antipsychotics.
Concurrent drug class with index drug OLZ
(N = 405)
RIS
(N = 276)
QUE
(N = 115)
p-value**
(OLZ vs QUE)
p-value**
(OLZ vs RIS)
p-value**
(RIS vs QUE)
Total days on index drug post 1 year after initiation 280 260 239 0.0028 0.0435 0.0557
First episode of continuously on index drug 272 250 225 0.0023 0.0908 0.0162
Total concurrent days on other antipsychotics*
on other atypicals 36.1 49.4 110.6 < 0.0001 0.0742 0.0001
on typicals 105.1 79.3 69.4 0.0107 0.0119 0.4723
on all anti-psychotics 136.6 120.3 160.2 0.1106 0.1378 0.0109
Percent of patients with >= 30 days of concurrent use
on other atypicals 18.5% 25.4% 52.2% < 0.0001 0.0322 < 0.0001
on typicals 48.2% 38.4% 33.0% 0.0041 0.0120 0.3171
on all anti-psychotics 61.7% 55.1% 72.2% 0.0396 0.0831 0.0017
* Total concurrent days of other antipsychotics while on the first episode of the index drug.
** Adjusted with comorbidity, age, race, gender, hospitalization status at initiation, schizoaffective diagnosis and insurance, site, time to initiation.BMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
Page 6 of 10
(page number not for citation purposes)
Average daily costs
The average daily cost of antipsychotics was calculated
while patients were on the first episode of their index
medication in the 1 year following its initiation. Almost
all index medication days on olanzapine, risperidone, and
quetiapine occurred in the first episode (97%, 96%, and
94%, respectively, Table 2). The average daily cost of the
index antipsychotic medication alone (Table 4) was the
highest for olanzapine ($10.08), followed by risperidone
($6.74) and quetiapine ($6.63). Lower total average daily
costs was observed in risperidone than olanzapine or
quetiapine. However, quetiapine-initiated patients were
significantly more likely to be coprescribed other atypical
antipsychotics (i.e., 110.6 days/year) than risperidone-ini-
tiated patients (49.4 days/year, p < .01) or olanzapine-ini-
tiated patients (36.1 days/year, p < .01) (Table 2), costing
an extra $7.44 per day on the coprescribed atypicals for
the quetiapine-initiated patient, $3.15 for the risperidone-
initiated patients (p < .01), and $2.02 for olanzapine-ini-
tiated patients (p < .01) (Table 4). In addition to concur-
rent use of other atypicals, there was also concurrent use
of typical antipsychotics. The average daily cost of the
coprescribed typical and atypical antipsychotics was sig-
nificantly higher for quetiapine ($8.70) compared to risp-
eridone ($4.30, p < .01) or olanzapine ($3.82, p < .01)
(Table 4). This cost was driven mainly by costs of copre-
scribed atypical antipsychotics. The total average daily
antipsychotic cost – of the index antipsychotic plus the
coprescribed antipsychotic medications (typical and/or
atypical) – was highest for quetiapine ($15.33), followed
by olanzapine ($13.90, p < .01) and risperidone ($11.04,
p < .01) (Table 4). Each dollar spent on the index atypical
antipsychotic was accompanied by spending an addi-
tional $1.31 ($8.70/6.63) on concomitant antipsychotic
medications for quetiapine compared to additional $0.64
($4.30/6.74) for risperidone and additional $0.38
($3.82/10.08) for olanzapine.
Using the median 2004 AWP to estimate the average daily
cost of all antipsychotics generated a similar pattern to
that obtained using 1998–1999 costs above. The esti-
mated 2004 daily costs were $20.74, $18.90, and $15.78
per day for quetiapine, olanzapine, and risperidone,
respectively with coprescribed antipsychotics being signif-
icantly higher for quetiapine ($11.13) compared to olan-
zapine ($4.29, p < .01) or risperidone ($4.76, p < .01)
(Figure 2).
Discussion
This study estimated total antipsychotic medication costs
in the usual care of patients with schizophrenia treated at
various health care settings in the United States when ini-
tiated on 1 of 3 commonly used atypical antipsychotics –
olanzapine, risperidone, and quetiapine. The 2
approaches used to calculate the costs were the average
daily cost while the patient is on the initiated index antip-
sychotic and the total annual antipsychotic medication
costs, reflecting intent-to-treat approach. The average
daily cost on the index atypical antipsychotic was signifi-
cantly higher for olanzapine compared to risperidone and
quetiapine groups. However, due to the presence of antip-
sychotic polypharmacy, each dollar spent on the index
antipsychotic was accompanied by an additional spend-
ing on other antipsychotics, such that each dollar spent on
quetiapine was associated with an additional $1.31 for
concomitant antipsychotics, compared to an additional
$0.64 for risperidone and an additional $0.38 for olanza-
pine. Thus, despite the significantly higher medication
Table 3: Total costs of index drugs and other antipsychotics in the post 1-year total cost.
Costs OLZ
(N = 405)
RIS
(N = 276)
QUE
(N = 115)
p-value*
(OLZ vs Que)
p-value*
(OLZ vs RIS)
p-value*
(RIS vs QUE)
Atypicals other index drug 868.04(1977.74) 1461.36(2615.2) 2938.38(3557.54) < 0.001 0.016 < 0.001
Typicals 662.2(1343.21) 474.18(936.99) 500.81(995.88) 0.30 0.034 0.82
All other antipsychotics 1530.23(2255.42) 1935.54(2703.68) 3439.18(3614.58) < 0.001 < 0.001 < 0.001
Index drug 3005.34(2163.62) 1877.92(1514.38) 1880.81(1766.23) 0.002 0.002 0.12
All antipsychotics including index drug 4535.57(3011.42) 3813.47(2890.79) 5320(3997.02) 0.002 0.004 0.002
* From 1000 iterations of bootstrap resampling.
Table 4: Daily cost of index and concomitant antipsychotics used during the first episode of index medication.
Costs OLZ
(N = 405)
RIS
(N = 276)
QUE
(N = 115)
p-value*
(OLZ vs Que)
p-value*
(OLZ vs RIS)
p-value*
(RIS vs QUE)
Concomitant atypicals 2.02(5.85) 3.15(6.85) 7.44(10.61) < 0.001 0.17 < 0.001
Concomitant typicals 1.79(4.08) 1.15(2.44) 1.26(2.96) 0.220 0.004 0.850
Concomitant antipsychotics 3.82(6.88) 4.30(7.07) 8.70(10.84) < 0.001 < 0.001 < 0.001
Index Drug 10.08(5.4) 6.74(3.81) 6.63(4.55) 0.002 0.002 0.140
All antipsychotics 13.9(8.97) 11.04(7.93) 15.33(11.71) 0.012 0.002 < 0.001
* From 1000 iterations of bootstrap resampling.BMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
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acquisition cost of olanzapine, the average daily antipsy-
chotic medication cost was found to be significantly
higher for quetiapine ($15.33) compared to olanzapine
($13.90) and risperidone ($11.04).
Similarly, the intent-to-treat annual antipsychotic medica-
tion cost for patients initiated on olanzapine ($4536) and
risperidone ($3813) was found to be significantly lower
than that for patients initiated on quetiapine ($5320), a
reduction in medication cost of $786 for olanzapine and
$1507 for risperidone. Importantly, these total antipsy-
chotic cost savings for patients initiated on olanzapine
compared to quetiapine were achieved despite longer
treatment duration with olanzapine at a higher drug
acquisition cost.
The primary cost driver of the expensive antipsychotic
polypharmacy practice associated with quetiapine therapy
appears to be the rates and duration of coprescribed atyp-
ical antipsychotic polypharmacy. As reported in our previ-
ous study [15], patients initiated on quetiapine had the
highest rate and longest duration of antipsychotic polyp-
harmacy among the 3 studied atypical antipsychotics, fol-
lowed by risperidone and olanzapine, thus increasing the
average daily and annual antipsychotic costs of treating
patients with schizophrenia. Note that the higher antipsy-
chotic medication costs associated with quetiapine ther-
apy was achieved despite the relatively low dose of
quetiapine used in this study. Low dose of quetiapine may
explain its lower medication acquisition costs compared
to olanzapine. In clinical practice, higher mean dose (620
mg) for quetiapine has been reported by Citrome and col-
leagues [30]. There is the possibility that quetiapine was
dosed too low in this study to be effective for some
patients leading to unnecessary costs of additional antip-
sychotics. At the same time, the 2-fold increase in quetiap-
Projected Total Daily Cost of All Antipsychotics Based on the Median 2004 AWP Figure 2
Projected Total Daily Cost of All Antipsychotics Based on the Median 2004 AWP. Projected total daily cost in U.S. 
dollars of all antipsychotics for patients initiated on olanzapine, quetiapine, and risperidone, using median 2004 average whole-
sales prices.BMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
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ine dose will considerably increase its acquisition costs
and overall medication costs.
To our best knowledge, this is the first study to assess the
cost of antipsychotic polypharmacy in the usual care of
patients with schizophrenia demonstrating that this com-
mon practice adds a substantial treatment cost and may
even double the medication cost of antipsychotic medica-
tion regimens. Current findings are consistent with previ-
ous research [19-21,31]. In a short-term, randomized,
double-blind study of risperidone, placebo, and quetiap-
ine for inpatients with schizophrenia [31], clinicians were
allowed to augment with other antipsychotics for a 4-
week duration following 2 weeks of monotherapy. That
study found the quetiapine group (mean dose 579.5 mg/
day) to be significantly more likely augmented with
another antipsychotic compared to risperidone, but with-
out significant or meaningful clinical benefits. The mean
cost of antipsychotic polypharmacy per randomized
patient was almost twice as high for the quetiapine group.
Findings of the present study, along with previous
research on the prevalent use of antipsychotic polyphar-
macy [3,4,6] and its unproven benefits [32,33] in the
treatment of schizophrenia, suggest that meaningful eco-
nomic comparisons among atypical antipsychotics can
only be achieved by incorporating the cost of antipsy-
chotic polypharmacy in the total medication cost calcula-
tions. Findings also suggest the need for additional
research to help clarify the underlying reasons for antipsy-
chotic polypharmacy in the treatment of patients with
schizophrenia in usual care.
Results of this study need to be evaluated in the context of
its limitation. First, this was a nonrandomized, noninter-
ventional, observational study; thus, treatment group
selection bias cannot be eliminated despite our use of sta-
tistical adjustments – with the propensity score-adjusted
bootstrapping method – for various available patient
characteristics at the time of medication initiation. Sec-
ond, this study focused on comparing costs associated
with the use of antipsychotics.
The use of other psychotropics may vary among treatment
groups and may contribute differentially to the total psy-
chiatric medication costs for different treatment groups.
Further studies on the use of all psychotropic medication
and its associated costs will provide a better understand-
ing of the costs associated with the use of various atypical
antipsychotics in the treatment of schizophrenia. It
should be noted that antipsychotics that were on generic
such as clozapine or are soon on generic such as risperi-
done and ziprasidone will be cheaper than their brand
names; therefore, the medication costs will be cheaper. In
addition, clozapine is an important atypical antipsychotic
medication in the treatment of schizophrenia. We decided
to only focus on polypharmacy costs associated with the
treatment of 3 most commonly used atypical antipsychot-
ics – olanzapine, quetiapine, and risperidone and, at the
same time, included any medication costs incurred by
clozapine when it was co-prescribed with any of the 3
study medications to ensure that the results and conclu-
sions from this study on the 3 medications are not
affected by the exclusion of clozapine as a comparative
treatment group. Ziprasidone and aripiprazole were not
included in this study due to lack of data for these 2 med-
ications. Ziprasidone was introduced in the United States
toward the end of US-SCAP, and aripiprazole was
launched after US-SCAP completion.
Finally, this study is unable to explain why there was a
greater propensity of olanzapine to be coprescribed with
typical antipsychotics and of quetiapine to be copre-
scribed with atypicals. The US-SCAP did not assess the rea-
sons for clinicians' medication choices, including the
reasons for medication initiation or augmentation. Clini-
cians may prescribe antipsychotics for different reasons to
patients with different illness profiles. As a result, the cost
advantage of olanzapine over quetiapine may be the
result of a biased pattern of prescribing unique to clini-
cians participating in this protocol. Fully understanding
and providing measures for the reasons behind the medi-
cation prescription pattern will help better address the
potential selection bias associated with an observational
study. In this study, we adjusted patient's demographics,
hospitalization, illness history, and other observable fac-
tors. Unobservable factors may still exist and may create
imbalance between the treatment groups.
Conclusion
Prevalent antipsychotic polypharmacy adds substantial
cost to the treatment of schizophrenia with significant
and meaningful differences in antipsychotic polyphar-
macy use patterns among atypical antipsychotics. Consist-
ent with previous research, schizophrenia patients
initiated with quetiapine appear more likely to receive
antipsychotic polypharmacy leading to an increase in
antipsychotic medication costs compared to olanzapine
and risperidone-initiated patients. Current findings,
based on treatment of schizophrenia patients in usual care
settings across the United States, have important eco-
nomic implications for formularies, health care insurers,
and the mental health system, indicating that the extra
costs of antipsychotic polypharmacy should be consid-
ered when evaluating the economic implications of treat-
ment with any specific antipsychotic medication. The
customary unilateral focus on the cost of the index antip-
sychotic medication acquisition alone does not accurately
reflect the incurred total costs of antipsychotic medica-
tions. A better understanding of the concomitant antipsy-
chotic costs provides for a more accurate portrayal ofBMC Psychiatry 2008, 8:19 http://www.biomedcentral.com/1471-244X/8/19
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antipsychotic medication costs in the treatment of schizo-
phrenia.
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